B of A Securities Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky has initiated coverage on Syndax Pharmaceuticals with a Buy rating and a price target of $29.
October 25, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals has been initiated with a Buy rating by B of A Securities, with a price target of $29.
The initiation of coverage by B of A Securities with a Buy rating and a price target of $29 indicates a positive outlook for Syndax Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100